Synthetic Pharmacotherapy for Systemic Lupus Erythematosus: Potential Mechanisms of Action, Efficacy, and Safety

Mostra/ Apri
Data
2022-12-27Autore
Téllez Arévalo, Angélica MaríaQuaye, Abraham
Rojas-Rodríguez, Luis Carlos
Poole, Brian D.
Baracaldo-Santamaría, Daniela
Tellez Freitas, Claudia M.
Autore/i aziendale
Pontificia Universidad Javeriana. Facultad de Medicina. Departamento de Ciencias Fisiológicas
Tipo
Artículo de revista
ISSN
1010-660X / 1648-9144 (Electrónico)
COAR
Artículo de revisiónCondividi questo record
Citación
Metadata
Mostra tutti i dati dell'item
Documenti PDF
Astratto
The pharmacological treatment of systemic lupus erythematosus (SLE) aims to decrease disease activity, progression, systemic compromise, and mortality. Among the pharmacological alternatives, there are chemically synthesized drugs whose efficacy has been evaluated, but which have the potential to generate adverse events that may compromise adherence and response to treatment. Therapy selection and monitoring will depend on patient characteristics and the safety profile of each drug. The aim of this review is to provide a comprehensive understanding of the most important synthetic drugs used in the treatment of SLE, including the current treatment options (mycophenolate mofetil, azathioprine, and cyclophosphamide), review their mechanism of action, efficacy, safety, and, most importantly, provide monitoring parameters that should be considered while the patient is receiving the pharmacotherapy.
Keywords
Immunosuppressant agentGlucocorticoid
Antimalarial drug
Efficacy
Safety
Systemic lupus erythematosus
Link alla risorsa
https://www.mdpi.com/1648-9144/59/1/56Editoriale
Medicina-Lithuania; Volumen 59 Número 1 , Páginas 1 - 47 (2022)
Google Analytics Statistics
Collections
- Artículos [28]